Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin.
Abnormal impulses caused by very slowly inactivating Na channels of peripheral nerve have been proposed to play a critical role in neuropathic pain. Low concentrations of local anesthetics, often effective in treating experimental and clinical neuropathic pain, are also known to potently suppress the long after-depolarizations induced by these persistently open Na channels. However, these drug actions on impulses that have propagated away from such sites are undetermined. In the present study, the focal application of anemone toxin II (ATX, 300 nM), which slows Na-channel inactivation, produced prolonged depolarizing after-potentials and, coincidentally, induced spontaneous bursting impulse activity that propagated away from the site of ATX application in the frog sciatic nerve in vitro. The application of low concentrations of lidocaine (1-10 microM), both at the site of ATX exposure and at a distant site, selectively and reversibly inhibited the spontaneous bursting, while having no effect on the electrically stimulated initial spike of the compound action potential. Inhibition occurred as a shortening of burst episodes rather than a reduction in frequency of impulses within a burst or a reduction of intraburst impulse amplitude. Tetrodotoxin also inhibited the induced spontaneous activity, but only at concentrations that also depressed the compound action potential spike. These findings show that low concentrations of lidocaine can restore normal firing patterns in nerve where hyperexcitability has been caused by delayed Na-channel inactivation, without acting directly at the site where ectopic impulses are generated. Thus, it appears that the pattern of abnormal activity rather than an abnormally gating Na channel per se can be a target for lidocaine's therapeutic action.
Persaud
Navindra
N
Pain Research Center, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Strichartz
Gary R
GR
D015761:4-Aminopyridine / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects; D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D003064:Cnidarian Venoms; D004558:Electric Stimulation; D008012:Lidocaine / Q000494:pharmacology*; D026902:Potassium Channel Blockers / Q000494:pharmacology; D011892:Rana catesbeiana; D011894:Rana pipiens; D012585:Sciatica / Q000139:chemically induced / Q000188:drug therapy*; D013779:Tetrodotoxin / Q000494:pharmacology
D000779:Anesthetics, Local; D003064:Cnidarian Venoms; D026902:Potassium Channel Blockers; D013779:Tetrodotoxin; C028800:toxin II (Anemonia sulcata); D008012:Lidocaine; D015761:4-Aminopyridine